Nasopharyngeal swab
Nasopharyngeal swab is an intervention with 35 clinical trials. Currently 4 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 20 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
0
Mid Stage
0
Late Stage
Highest Phase Reached
UnknownTrial Status & Enrollment
95.2%
20 of 21 finished
4.8%
1 ended early
4
trials recruiting
35
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study of the Immunological and Virological Response of Patients With COVID-19 and Presenting an Asymptomatic or Pauci-symptomatic Form (AMBUCOV)
Evaluation of a Screening Program for SARS-CoV-2 Infection in the General Population Based on the Use of New Detection Approaches or for Diagnostic Orientation on Saliva
Dynamics of the Upper and Lower Airway Respiratory Microbiomes Associated With Severe Infant Asthma
Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19
Contribution of Pathological Alpha-synuclein as a Diagnostic Biomarker for Dementia With Lewy Bodies
Clinical Trials (35)
Study of the Immunological and Virological Response of Patients With COVID-19 and Presenting an Asymptomatic or Pauci-symptomatic Form (AMBUCOV)
Evaluation of a Screening Program for SARS-CoV-2 Infection in the General Population Based on the Use of New Detection Approaches or for Diagnostic Orientation on Saliva
Dynamics of the Upper and Lower Airway Respiratory Microbiomes Associated With Severe Infant Asthma
Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19
Contribution of Pathological Alpha-synuclein as a Diagnostic Biomarker for Dementia With Lewy Bodies
An Evaluation of PCV13 Vaccine Schedules, Comparing Impact of 2+1 vs 3+0 on Pneumococcal Carriage in Blantyre, Malawi
A Research Platform to Screen Healthcare Workers- Coordinated Approach to Pandemic Trials of COVID-19
Evaluation of the Diagnostic Performance of the TestNPass DM-DIV for SARS-CoV-2 Using a Nasopharyngeal Sample
Nosocomial Respiratory Virus Infection
Impact of Bacterial Expression and Immune Response in the Severity of Pertussis
Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo
Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test
Impact of COVID-19 SARS-CoV-2 Variability in ICU Hospitalized Patients With Severe Disease
PCV13 Impact on Pneumococcal Nasopharyngeal Carriage Study
Improving the Diagnosis of Pneumonia in Emergency Rooms
Improving the Diagnosis of Tonsillitis in Emergency Rooms
Improving the Diagnosis of Diarrhoea in Emergency Rooms
Improving the Diagnosis of Meningitis in Emergency Rooms
Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag ULTRA Test (ASPIRE-2)
RESCEU: Defining the Burden of RSV Disease
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 35